[
  {
    "ts": "2026-02-24T07:11:59+00:00",
    "headline": "FDA Accepts Regeneron (REGN) BLA for Garetosmab Under Priority Review",
    "summary": "Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best value stocks to buy now. On February 19, Regeneron Pharmaceuticals announced that the FDA accepted its BLA for garetosmab for Priority Review. This investigational monoclonal antibody is designed to treat adults with fibrodysplasia ossificans progressiva/FOP, which is an ultra-rare and devastating genetic disorder where muscles and […]",
    "url": "https://finance.yahoo.com/news/fda-accepts-regeneron-regn-bla-071159555.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "4279ff7d-3383-3521-9fe4-b3e6997b71b1",
      "content": {
        "id": "4279ff7d-3383-3521-9fe4-b3e6997b71b1",
        "contentType": "STORY",
        "title": "FDA Accepts Regeneron (REGN) BLA for Garetosmab Under Priority Review",
        "description": "",
        "summary": "Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the best value stocks to buy now. On February 19, Regeneron Pharmaceuticals announced that the FDA accepted its BLA for garetosmab for Priority Review. This investigational monoclonal antibody is designed to treat adults with fibrodysplasia ossificans progressiva/FOP, which is an ultra-rare and devastating genetic disorder where muscles and […]",
        "pubDate": "2026-02-24T07:11:59Z",
        "displayTime": "2026-02-24T07:11:59Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4b91a17abc1798c6665547c7b72ba5ee",
          "originalWidth": 1271,
          "originalHeight": 1280,
          "caption": "FDA Accepts Regeneron (REGN) BLA for Garetosmab Under Priority Review",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TkrNiAYKS4sSLbgJB2p6rg--~B/aD0xMjgwO3c9MTI3MTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/4b91a17abc1798c6665547c7b72ba5ee.cf.webp",
              "width": 1271,
              "height": 1280,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8w3yEMtyFUWzQ67I_iaIMw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4b91a17abc1798c6665547c7b72ba5ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fda-accepts-regeneron-regn-bla-071159555.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-accepts-regeneron-regn-bla-071159555.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T14:30:00+00:00",
    "headline": "Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)",
    "summary": "Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurrence Dupixent is now approved in the U.S. to treat nine distinct diseases driven in part by type 2 infl",
    "url": "https://finance.yahoo.com/news/dupixent-dupilumab-approved-u-first-143000422.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "4e6b69fd-e18b-39b3-822b-1b1dfe3abee9",
      "content": {
        "id": "4e6b69fd-e18b-39b3-822b-1b1dfe3abee9",
        "contentType": "STORY",
        "title": "Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)",
        "description": "",
        "summary": "Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurrence Dupixent is now approved in the U.S. to treat nine distinct diseases driven in part by type 2 infl",
        "pubDate": "2026-02-24T14:30:00Z",
        "displayTime": "2026-02-24T14:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142",
          "originalWidth": 800,
          "originalHeight": 126,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ohIVokMiKClSVTQVwyB2lw--~B/aD0xMjY7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142.cf.webp",
              "width": 800,
              "height": 126,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YuYzNeQcIK6rRYN1HdT6UA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2788fcd6c9b4dcf523fc2cc341eb4142.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/dupixent-dupilumab-approved-u-first-143000422.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/dupixent-dupilumab-approved-u-first-143000422.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T23:14:52+00:00",
    "headline": "Should FDA Approval of Dupixent in AFRS Patients Prompt Action From Regeneron Pharmaceuticals (REGN) Investors?",
    "summary": "On 24 February 2026, Regeneron and Sanofi reported that the FDA approved Dupixent for allergic fungal rhinosinusitis in patients aged six and older with prior sino-nasal surgery. This first AFRS-specific therapy, backed by strong Phase 3 data showing improved sinus disease control and reduced need for steroids or surgery, further broadens Dupixent’s inflammatory disease footprint. We’ll now assess how this new AFRS indication for Dupixent, which targets a hard-to-treat chronic sinus disease,...",
    "url": "https://finance.yahoo.com/news/fda-approval-dupixent-afrs-patients-231452990.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "25b61381-fabc-36e9-b98b-77c40206c64f",
      "content": {
        "id": "25b61381-fabc-36e9-b98b-77c40206c64f",
        "contentType": "STORY",
        "title": "Should FDA Approval of Dupixent in AFRS Patients Prompt Action From Regeneron Pharmaceuticals (REGN) Investors?",
        "description": "",
        "summary": "On 24 February 2026, Regeneron and Sanofi reported that the FDA approved Dupixent for allergic fungal rhinosinusitis in patients aged six and older with prior sino-nasal surgery. This first AFRS-specific therapy, backed by strong Phase 3 data showing improved sinus disease control and reduced need for steroids or surgery, further broadens Dupixent’s inflammatory disease footprint. We’ll now assess how this new AFRS indication for Dupixent, which targets a hard-to-treat chronic sinus disease,...",
        "pubDate": "2026-02-24T23:14:52Z",
        "displayTime": "2026-02-24T23:14:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w30LARiR1Z35GusfaFi.2g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3eDp_RSETU8kXm3usDK_gQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/a52f4d4b48157c0b8b51190845e3ba14.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fda-approval-dupixent-afrs-patients-231452990.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-approval-dupixent-afrs-patients-231452990.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            },
            {
              "symbol": "SNY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]